|1.||Okada, Hiroaki: 2 articles (08/2011 - 01/2011)|
|2.||Takashima, Yuuki: 1 article (08/2011)|
|3.||Uchida, Tamae: 1 article (08/2011)|
|4.||Kawai, Misako: 1 article (08/2011)|
|5.||Kanazawa, Takanori: 1 article (08/2011)|
|6.||Strober, Warren: 1 article (11/2008)|
|7.||Marinaro, Mariarosaria: 1 article (11/2008)|
|8.||Kitani, Atsushi: 1 article (11/2008)|
|9.||Butera, Alessia: 1 article (11/2008)|
|10.||Fuss, Ivan J: 1 article (11/2008)|
11/01/2008 - "Both ethanol and AT1002 induced persistent latency-associated peptide-positive CD4(+) regulatory T cells that, as shown in adoptive transfer studies, render mice resistant to the induction of TNBS colitis. "
11/01/2008 - "The effects of ethanol and AT1002 on colon immune function were evaluated by their capacity to induce direct phenotypic or functional changes in effector and regulatory cell populations and their indirect effect on the development of TNBS-induced colitis. "
11/01/2008 - "We determined the effect of agents that disrupt epithelial tight junctions (ethanol and AT1002, a Vibrio cholerae zonula occludens toxin hexapeptide) on regulatory T-cell induction and resistance to induction of colitis by trinitrobenzene sulfonic acid (TNBS). "
|2.||Atopic Dermatitis (Atopic Eczema)
01/01/2011 - "Tat and AT1002 analogs used to treat atopic dermatitis in mice increased cell membrane permeability to siRelA, a siRNA against a subclass of NF-κB, and exhibited striking therapeutic and preventive effects."
08/01/2011 - "Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002."
|1.||Ethanol (Ethyl Alcohol)
|2.||Small Interfering RNA (siRNA)
|4.||Vibrio cholerae zonula occludens toxin